When surgery is not an option for treatment of hepatocellular carcinoma, arterial chemoembolization, but not tamoxifen, may prolong survival of patients with advanced disease, reported Spanish researchers here at the 53rd Annual Meeting of the American Association for the Study of Liver Diseases.
In a meta-analysis of randomized controlled trials, Josep Llovet, MD, and colleagues from the University of Barcelona, Spain, found that “chemoembolization improves survival in a subset of patients with unresectable hepatocellular carcinoma, and may be considered the standard treatment for them. Tamoxifen does not modify survival of patients with advanced disease.”
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!